# EDGAR Filing Document

**Accession Number:** 0000927653
**File Stem:** 0000927653-23-000015
**Filing Date:** 2023-2
**Character Count:** 87848
**Document Hash:** 139688177026ea2f654e217ab28eb3fa
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000927653-23-000015.hdr.sgml**: 20230201

**ACCESSION NUMBER**: 0000927653-23-000015

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 16

**CONFORMED PERIOD OF REPORT**: 20230201

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230201

**DATE AS OF CHANGE**: 20230201

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MCKESSON CORP
- **CENTRAL INDEX KEY:** 0000927653
- **STANDARD INDUSTRIAL CLASSIFICATION:** WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
- **IRS NUMBER:** 943207296
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-13252
- **FILM NUMBER:** 23576764

**BUSINESS ADDRESS:**
- **STREET 1:** 6555 STATE HIGHWAY 161
- **CITY:** IRVING
- **STATE:** TX
- **ZIP:** 75039
- **BUSINESS PHONE:** 972-446-4800

**MAIL ADDRESS:**
- **STREET 1:** 6555 STATE HIGHWAY 161
- **CITY:** IRVING
- **STATE:** TX
- **ZIP:** 75039

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MCKESSON HBOC INC
- **DATE OF NAME CHANGE:** 19990115

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MCKESSON CORP
- **DATE OF NAME CHANGE:** 19950209

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SP VENTURES INC
- **DATE OF NAME CHANGE:** 19940728

?xml version="1.0" ? mck-20230201

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K** 

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)** 

**of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): February 1, 2023**![mck-20230201_g1.jpg](mck-20230201_g1.jpg)

**McKESSON CORPORATION** 

**(Exact Name of Registrant as Specified in Charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **1-13252** | **94-3207296** |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission<br>File Number)** | **(I.R.S. Employer<br>Identification No.)** |

---

**6555 State Hwy 161** 

**Irving, TX 75039** 

**(Address of Principal Executive Offices, and Zip Code)**

**(972) 446-4800** 

**Registrant's Telephone Number, Including Area Code**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br>Symbol(s)** | **Name of each exchange<br>on which registered** |
| Common stock, $0.01 par value | MCK | New York Stock Exchange |
| 1.500% Notes due 2025 | MCK25 | New York Stock Exchange |
| 1.625% Notes due 2026 | MCK26 | New York Stock Exchange |
| 3.125% Notes due 2029 | MCK29 | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 &nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition.**

On February 1, 2023, McKesson Corporation ("Company") reported the Company's preliminary results for the quarter ended on December 31, 2022 which are attached hereto as Exhibit 99.1.

The information contained in this Form 8-K, including Exhibit 99.1, is furnished to the Securities and Exchange Commission (the "Commission"), but shall not be deemed "filed" with the Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01 &nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | <u>[Earnings release issued by the Company dated February 1, 2023](mck_exhibit991x12312022.htm)</u> |
| 104 | Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the Inline XBRL document |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 1, 2023

---

| | |
|:---|:---|
| **McKesson Corporation** | **McKesson Corporation** |
| By: | /s/ Britt J. Vitalone |
|  | Britt J. Vitalone |
|  | Executive Vice President and |
|  | Chief Financial Officer |

---

## Exhibit 99.1

![mckessonlogoa03a.jpg](mckessonlogoa03a.jpg)

**McKESSON CORPORATION REPORTS FISCAL 2023 THIRD-QUARTER RESULTS**

**AND RAISES FULL-YEAR GUIDANCE**

**Third-Quarter Highlights:** 

• Total revenues of $70.5 billion increased 3%.

• Earnings per diluted share from continuing operations of $7.65 increased $7.69.

• Adjusted Earnings per Diluted Share of $6.90 increased 12%.

• Adjusted Earnings per Diluted Share Excluding Certain Items increased 6%.

**<br>Fiscal 2023 Outlook:**

• Increased fiscal 2023 Adjusted Earnings per Diluted Share guidance range to $25.75 to $26.15, from the previous range of $24.45 to $24.95.

• Fiscal 2023 Adjusted Earnings per Diluted Share guidance includes approximately $2.30 to $2.50, an increase from the previous range of $1.45 to $1.65, attributable to the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ $0.70 to $0.80 related to the U.S. government's COVID-19 vaccine distribution program;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ $1.10 to $1.20 related to the U.S. government's kitting, storage, and distribution of ancillary supplies program and COVID-19 tests;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Approximately ($0.15) related to year-to-date net gains and losses associated with McKesson Ventures' equity investments;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ $0.65 related to the termination of the tax receivable agreement with Change Healthcare.

• Fiscal 2023 Adjusted Earnings per Diluted Share Excluding Certain Items guidance indicates 13% to 16% forecasted growth compared to prior year.

**IRVING, Texas, February 1, 2023 -** McKesson Corporation (NYSE:MCK) today reported results for the third-quarter ended December 31, 2022.

**Fiscal 2023 Third-Quarter Result Summary**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Third-Quarter** | **Third-Quarter** | **Third-Quarter** | **Year-to-Date** | **Year-to-Date** | **Year-to-Date** |
| *<u>($ in millions, except per share amounts)</u>* | **FY23** | **FY22** | **Change** | **FY23** | **FY22** | **Change** |
| **Revenues** | $70490 | $68614 | 3% | $207801 | $197864 | 5% |
| **Income from Continuing Operations** <sup>1</sup> | 1078 | (7) |  | 2776 | 749 | 271 |
| **Adjusted Earnings** <sup>1,2</sup> | 972 | 944 | 3 | 2697 | 2782 | (3) |
| **Earnings per Diluted Share** <sup>1</sup> | 7.65 | (0.04) |  | 19.32 | 4.81 | 302 |
| **Adjusted Earnings per Diluted Share** <sup>1,2</sup> | 6.90 | 6.15 | 12 | 18.78 | 17.86 | 5 |
| <sup>1</sup> Reflects continuing operations attributable to McKesson, net of tax<br><sup>2</sup> Adjusted results in this earnings release are non-GAAP financial measures; refer to the accompanying definitions and reconciliation schedules | <sup>1</sup> Reflects continuing operations attributable to McKesson, net of tax<br><sup>2</sup> Adjusted results in this earnings release are non-GAAP financial measures; refer to the accompanying definitions and reconciliation schedules | <sup>1</sup> Reflects continuing operations attributable to McKesson, net of tax<br><sup>2</sup> Adjusted results in this earnings release are non-GAAP financial measures; refer to the accompanying definitions and reconciliation schedules | <sup>1</sup> Reflects continuing operations attributable to McKesson, net of tax<br><sup>2</sup> Adjusted results in this earnings release are non-GAAP financial measures; refer to the accompanying definitions and reconciliation schedules | <sup>1</sup> Reflects continuing operations attributable to McKesson, net of tax<br><sup>2</sup> Adjusted results in this earnings release are non-GAAP financial measures; refer to the accompanying definitions and reconciliation schedules | <sup>1</sup> Reflects continuing operations attributable to McKesson, net of tax<br><sup>2</sup> Adjusted results in this earnings release are non-GAAP financial measures; refer to the accompanying definitions and reconciliation schedules | <sup>1</sup> Reflects continuing operations attributable to McKesson, net of tax<br><sup>2</sup> Adjusted results in this earnings release are non-GAAP financial measures; refer to the accompanying definitions and reconciliation schedules |

---

&nbsp;&nbsp;&nbsp;&nbsp;<br>&nbsp;&nbsp;&nbsp;&nbsp;"McKesson delivered another solid quarter, driven by the dedication of our talented associates committed to advancing healthcare for all. Our performance was highlighted by execution across our scaled distribution businesses and differentiated capabilities in the oncology and biopharma services platforms," said Brian Tyler, chief executive officer. "This consistently solid performance, combined with our outlook, reinforces our ability to deliver on our financial targets, resulting in compelling value creation for all stakeholders. As a result of our execution and operational strength, we are raising our fiscal 2023 Adjusted Earnings per Diluted Share guidance to $25.75 to $26.15."

------

Third-quarter revenues were $70.5 billion, an increase of 3% from a year ago, primarily driven by growth in the U.S. Pharmaceutical segment, resulting from increased specialty product volumes, including retail national account customers, market growth, and strength across the oncology platform including increased patient visits partially offset by lower revenues in the International segment as a result of the completed divestitures of McKesson's European businesses.

Third-quarter earnings per diluted share from continuing operations was $7.65 compared to loss per diluted share from continuing operations of ($0.04) a year ago, an increase of $7.69, due to an after-tax charge of $829 million for the fair value remeasurement related to McKesson's agreement to sell its UK business in the third-quarter of fiscal 2022.

Third-quarter Adjusted Earnings per Diluted Share was $6.90 compared to $6.15 a year ago, an increase of 12%, driven by lower corporate expenses, including a pre-tax benefit of $126 million associated with the termination of the tax receivable agreement with Change Healthcare, lower share count, and growth across the North American businesses.

For the first nine months of the fiscal year, McKesson returned $3.7 billion of cash to shareholders, which included $3.5 billion of common stock repurchases and $216 million of dividend payments. During the first nine months of the fiscal year, McKesson generated cash from operations of $1.8 billion, and invested more than $300 million in capital expenditures, resulting in Free Cash Flow of $1.5 billion.

**Business Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• McKesson was recognized by Newsweek as one of America's Greatest Workplaces for Diversity in 2023.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The Science Based Targets initiative (SBTi) has approved McKesson's near-term science-based greenhouse gas (GHG) emissions reduction targets. The targets validated by SBTi are to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Reduce direct GHG emissions 50% by fiscal 2032 from a fiscal 2020 base year

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Ensure 70% of McKesson suppliers, by spend covering purchased goods and services, will have their own SBTi-approved GHG reduction targets by fiscal 2027

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• McKesson continued to expand its differentiated oncology and biopharma businesses, further demonstrating meaningful progress against its company priorities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ On October 31, 2022, McKesson and HCA Healthcare completed the formation of a joint venture combining McKesson's US Oncology Research and HCA Healthcare's Sarah Cannon Research Institute and on November 1, 2022, McKesson completed the acquisition of Rx Savings Solutions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ The US Oncology Network expanded its footprint into local communities with the addition of two large multidisciplinary practices, Epic Care and Nexus Health.

**U.S. Pharmaceutical Segment**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Third-quarter revenues were $61.9 billion, an increase of 13%, driven by increased volume of specialty products, including higher volumes from retail national account customers, and market growth, partially offset by branded to generic conversions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Third-quarter Segment Operating Profit was $850 million. Adjusted Segment Operating Profit was $778 million, an increase of 6%, driven by growth in distribution of specialty products to providers and health systems. Excluding the impact of COVID-19 vaccine distribution, the U.S. Pharmaceutical segment delivered Adjusted Segment Operating Profit growth of 7%, driven by growth in distribution of specialty products to providers and health systems and improvements in pharmaceutical prescription volumes and oncology visits.

------

**Prescription Technology Solutions Segment**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Third-quarter revenues were $1.1 billion, an increase of 9%, driven by growth in prescription volumes in our third-party logistics business and higher technology service revenues.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Third-quarter Segment Operating Profit was $136 million. Adjusted Segment Operating Profit was $155 million, an increase of 7%, driven by growth in access, affordability, and adherence solutions. During the quarter, we continued to organically invest in this segment as we position our products and services for sustainable long-term growth.

**Medical-Surgical Solutions Segment**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Third-quarter revenues were $3.0 billion, a decrease of 3%, driven by lower sales of COVID-19 tests and lower contribution from kitting, storage, and distribution of ancillary supplies for the U.S. government's COVID-19 vaccine program, partially offset by growth in the primary care business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Third-quarter Segment Operating Profit was $328 million. Adjusted Segment Operating Profit was $336 million, an increase of 2%, driven by growth in the primary care business and organic business performance, partially offset by lower sales of COVID-19 tests and lower contribution from kitting, storage, and distribution of ancillary supplies for the U.S. government's COVID-19 vaccine program. Excluding the impact of COVID-19 related items, the Medical-Surgical Solutions segment delivered Adjusted Segment Operating Profit growth of 25%, driven by growth in the primary care business, including illness season testing, and favorable sourcing activities.

**International Segment**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Third-quarter revenues were $4.4 billion. On an FX-Adjusted basis, revenues were $4.9 billion, a decrease of 48%, driven by the divestitures of McKesson's European businesses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Third-quarter Segment Operating Profit was $136 million. On an FX-Adjusted basis, Adjusted Segment Operating Profit was $158 million, a decrease of 29%, driven by the divestitures of McKesson's European businesses.

**Fiscal 2023 Outlook**

McKesson raised fiscal 2023 Adjusted Earnings per Diluted Share guidance to $25.75 to $26.15 from the previous range of $24.45 to $24.95 to reflect solid operating business performance.

Fiscal 2023 Adjusted Earnings per Diluted Share guidance includes approximately $2.30 to $2.50 of impacts attributable to the following:

---

| | | |
|:---|:---|:---|
| | **February 2023**<br>**Outlook** | **November 2022**<br>**Outlook** |
| U.S. government's COVID-19 vaccine distribution program | $0.70 to $0.80 | $0.60 to $0.70 |
| U.S. government's kitting, storage, and distribution of ancillary supplies program and COVID-19 tests | $1.10 to $1.20 | $1.00 to $1.10 |
| Net gains and losses associated with McKesson Ventures' equity investments | Approximately ($0.15) | Approximately ($0.15) |
| Termination of the tax receivable agreement with Change Healthcare | $0.65 | -- |
| &nbsp;&nbsp;**Total Impact of Certain Items** | **$2.30 to $2.50** | **$1.45 to $1.65** |

---

Fiscal 2023 Adjusted Earnings per Diluted Share Excluding Certain Items guidance indicates 13% to 16% forecasted growth compared to prior year.

Additional modeling considerations will be provided in the earnings call presentation.

------

**Conference Call Details**

McKesson has scheduled a conference call for today, Wednesday, February 1<sup>st</sup> at 4:30 PM ET to discuss the company's financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website at <u>investor.mckesson.com.</u>

**Upcoming Investor Events**

McKesson management will be participating in the following investor conference:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• BofA Securities 2023 Healthcare Conference, May 9-11, 2023

Audio webcast, and a complete listing of upcoming events for the investment community, including details and updates, will be available on McKesson's Investor Relations website.

**Non-GAAP Financial Measures**

GAAP refers to the U.S. generally accepted accounting principles. This press release includes GAAP financial measures as well as Non-GAAP financial measures, including Adjusted Gross Profit, Adjusted Operating Expenses, Adjusted Other Income, Adjusted Loss on Debt Extinguishment, Adjusted Income Tax Expense, Adjusted Earnings, Adjusted Earnings per Diluted Share, Adjusted Earnings per Diluted Share Excluding Certain Items, Adjusted Segment Operating Profit, Adjusted Segment Operating Profit Margin, Adjusted Corporate Expenses, Adjusted Operating Profit, FX-Adjusted results and Free Cash Flow which are financial measures not calculated in accordance with GAAP. Refer to the "Supplemental Non-GAAP Financial Information" section of the accompanying financial statement tables for the definitions and usefulness of the Company's Non-GAAP financial measures and the attached schedules for reconciliations of the differences between the Non-GAAP financial measures and their most directly comparable GAAP financial measures.

The Company does not provide forward-looking guidance on a GAAP basis as McKesson is unable to provide a quantitative reconciliation of this forward-looking Non-GAAP measure to the most directly comparable forward-looking GAAP measure, without unreasonable effort, because McKesson cannot reliably forecast LIFO inventory-related adjustments, certain litigation loss and gain contingencies, restructuring, impairment and related charges, and other adjustments, which are difficult to predict and estimate. These items are inherently uncertain and depend on various factors, many of which are beyond the company's control, and as such, any associated estimate and its impact on GAAP performance could vary materially.

**Cautionary Statements** 

This earnings release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by their use of terminology such as "believes," "expects," "anticipates," "may," "will," "should," "seeks," "approximately," "intends," "projects," "plans," "estimates," "targets" or the negative of these words or other comparable terminology. The discussion of financial outlook, guidance, trends, strategy, plans, assumptions, or intentions, and our greenhouse gas emission targets may also include forward-looking statements. Readers should not place undue reliance on forward-looking statements, such as financial performance forecasts, which speak only as of the date they are first made. Except to the extent required by law, we undertake no obligation to update or revise our forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Although it is not possible to predict or identify all such risks and uncertainties, we encourage investors to read the risk factors described in our most recent annual and periodic report filed with the Securities and Exchange Commission.

------

These risk factors include, but are not limited to: we experience costly and disruptive legal disputes and settlements, including regarding our role in distributing controlled substances such as opioids; we might experience losses not covered by insurance; we might be adversely impacted by changes in tax legislation or challenges to our tax positions; we from time to time record significant charges from impairment to goodwill, intangibles, inventory and other assets or investments; we experience cybersecurity incidents and might experience significant computer system compromises or data breaches; we might experience significant problems with information systems or networks; we may be unsuccessful in retail pharmacy profitability; we might be harmed by large customer purchase reductions, payment defaults or contract non-renewal; our contracts with government entities involve future funding and compliance risks; we might be harmed by changes in our relationships or contracts with suppliers; we might be adversely impacted by delays or other difficulties with divestitures; we might be adversely impacted by healthcare reform such as changes in pricing and reimbursement models; we might be adversely impacted by changes or disruptions in product supply and we have experienced and may experience difficulties in sourcing products and changes in pricing due to the effects of the COVID-19 pandemic and Russo-Ukrainian War on supply chains; we might be adversely impacted as a result of our distribution of generic pharmaceuticals; we might be adversely impacted by an economic slowdown or recession and by disruption in capital and credit markets that might impede our access to credit, increase our borrowing costs and impair the financial soundness of our customers and suppliers; we might be adversely impacted by monetary inflation or fluctuations in foreign currency exchange rates; we might be adversely impacted by events outside of our control, such as widespread public health issues (including the effects we have experienced from the COVID-19 pandemic), natural disasters, political events (such as the Russo-Ukrainian War) and other catastrophic events; we may not achieve our GHG emissions reduction targets; SBTi may not validate a sufficient number of our suppliers' GHG reduction targets; we may incur additional costs or operational impacts related to our GHG reduction initiatives; we may be adversely affected by global climate change or by legal, regulatory or market responses to such change; and we face uncertainties and risks related to COVID-19 vaccination distribution and related ancillary supply kit programs.

**About McKesson Corporation**

McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at <u>McKesson.com</u> and read <u>Our Stories</u>.

**Contacts:**

Rachel Rodriguez, 469-260-0556 (Investors)

<u>Rachel.Rodriguez@McKesson.com</u>

David Matthews, 214-952-0833 (Media)

<u>David.Matthews@McKesson.com</u>

------

***<u>Schedule 1</u>***

**McKESSON CORPORATION**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (GAAP)**

**(unaudited)**

**(in millions, except per share amounts)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | | **Nine Months Ended December 31,** | **Nine Months Ended December 31,** | |
| | **2022** | **2021** |<br>**Change** | **2022** | **2021** |<br>**Change** |
| Revenues | $70490 | $68614 | 3% | $207801 | $197864 | 5% |
| Cost of sales | (67316) | (65186) | 3 | (198509) | (188052) | 6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gross profit | 3174 | 3428 | (7) | 9292 | 9812 | (5) |
| Selling, distribution, general, and administrative expenses | (1903) | (3105) | (39) | (5812) | (8006) | (27) |
| Claims and litigation charges, net | 1 | (7) | 114 | 5 | (193) | 103 |
| Restructuring, impairment, and related charges, net | (31) | (18) | 72 | (84) | (208) | (60) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | (1933) | (3130) | (38) | (5891) | (8407) | (30) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating income | 1241 | 298 | 316 | 3401 | 1405 | 142 |
| Other income, net | 276 | 20 |  | 466 | 202 | 131 |
| Loss on debt extinguishment |  |  |  |  | (191) | (100) |
| Interest expense | (69) | (41) | 68 | (169) | (135) | 25 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income from continuing operations before income taxes | 1448 | 277 | 423 | 3698 | 1281 | 189 |
| Income tax expense | (329) | (238) | 38 | (799) | (396) | 102 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income from continuing operations | 1119 | 39 |  | 2899 | 885 | 228 |
| Income (loss) from discontinued operations, net of tax | 1 |  |  | (3) | (3) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income | 1120 | 39 |  | 2896 | 882 | 228 |
| Net income attributable to noncontrolling interests | (41) | (46) | (11) | (123) | (136) | (10) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) attributable to McKesson Corporation | $1079 | $(7) | —% | $2773 | $746 | 272% |
| Earnings (loss) per common share attributable to McKesson Corporation <sup>(a)</sup>  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted <sup>(b)</sup> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Continuing operations | $7.65 | $(0.04) | —% | $19.32 | $4.81 | 302% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Discontinued operations | 0.01 |  |  | (0.02) | (0.02) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $7.66 | $(0.04) | —% | $19.30 | $4.79 | 303% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Continuing operations | $7.70 | $(0.04) | —% | $19.48 | $4.87 | 300% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Discontinued operations | 0.01 |  |  | (0.02) | (0.02) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $7.71 | $(0.04) | —% | $19.46 | $4.85 | 301% |
| Dividends declared per common share | $0.54 | $0.47 |  | $1.55 | $1.36 |  |
| Weighted-average common shares outstanding |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | 141.0 | 151.6 | (7)% | 143.7 | 155.8 | (8)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | 139.9 | 151.6 | (8) | 142.5 | 154.0 | (7) |

---

(a)Certain computations may reflect rounding adjustments.

(b)Net loss per diluted share for the three months ended December 31, 2021 is calculated by excluding dilutive securities from the denominator due to their antidilutive effects.

All percentage changes displayed above which are not meaningful are displayed as zero percent.

Refer to our applicable filings with the SEC for additional disclosures including our Quarterly Reports on Form 10-Q for fiscal 2023 and 2022 as well as our

Annual Report on Form 10-K for fiscal 2022.

------

***<u>Schedule 2</u>***

**McKESSON CORPORATION**

**RECONCILIATION OF GAAP OPERATING RESULTS TO ADJUSTED RESULTS (NON-GAAP)** 

**(unaudited)**

**(in millions)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | | **Nine Months Ended December 31,** | **Nine Months Ended December 31,** | |
| | **2022** | **2021** |<br>**Change** | **2022** | **2021** |<br>**Change** |
| Income from continuing operations (GAAP) | $1119 | $39 | —% | $2899 | $885 | 228% |
| Net income attributable to noncontrolling interests (GAAP) | (41) | (46) | (11) | (123) | (136) | (10) |
| **Income (loss) from continuing operations attributable to McKesson Corporation (GAAP)** | 1078 | (7) |  | 2776 | 749 | 271 |
| Pre-tax adjustments: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of acquisition-related intangibles | 57 | 81 | (30) | 170 | 263 | (35) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transaction-related expenses and adjustments <sup>(1) (2) (3) (4) (5)</sup> | (9) | 882 | (101) | (158) | 1343 | (112) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LIFO inventory-related adjustments | 5 | (33) | 115 | (31) | (79) | (61) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gains from antitrust legal settlements | (129) |  |  | (129) | (46) | 180 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring, impairment, and related charges, net <sup>(6)</sup> | 31 | 18 | 72 | 84 | 208 | (60) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Claims and litigation charges, net <sup>(7)</sup> | (1) | 7 | (114) | (5) | 193 | (103) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other adjustments, net <sup>(8) (9) (10)</sup> | (78) |  |  | (71) | 347 | (120) |
| Income tax effect on pre-tax adjustments | 18 | (4) | 550 | 61 | (196) | 131 |
| **Adjusted Earnings (Non-GAAP)** | $972 | $944 | 3% | $2697 | $2782 | (3)% |

---

All percentage changes displayed above which are not meaningful are displayed as zero percent.

Refer to the section entitled "Financial Statement Notes" of this release.

For more information relating to the Adjusted Earnings (Non-GAAP) definition, refer to the section entitled "Supplemental Non-GAAP Financial Information" of this release.

------

***<u>Schedule 2 (continued)</u>***

**McKESSON CORPORATION**

**RECONCILIATION OF GAAP OPERATING RESULTS TO ADJUSTED RESULTS (NON-GAAP)**

**(unaudited)**

**(in millions, except per share amounts)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | | **Nine Months Ended December 31,** | **Nine Months Ended December 31,** | |
| | **2022** | **2021** |<br>**Change** | **2022** | **2021** |<br>**Change** |
| **Earnings (loss) per diluted common share from continuing operations attributable to McKesson Corporation (GAAP)** <sup>(a) (b)</sup> | $7.65 | $(0.04) | —% | $19.32 | $4.81 | 302% |
| After-tax adjustments: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of acquisition-related intangibles | 0.32 | 0.42 | (24) | 0.93 | 1.33 | (30) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transaction-related expenses and adjustments | (0.17) | 5.80 | (103) | (0.70) | 8.55 | (108) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LIFO inventory-related adjustments | 0.03 | (0.16) | 119 | (0.16) | (0.38) | (58) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gains from antitrust legal settlements | (0.67) |  |  | (0.66) | (0.22) | 200 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring, impairment, and related charges, net | 0.17 | 0.09 | 89 | 0.45 | 1.07 | (58) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Claims and litigation charges, net | (0.01) | 0.04 | (125) | (0.03) | 1.03 | (103) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other adjustments, net | (0.42) |  |  | (0.37) | 1.67 | (122) |
| **Adjusted Earnings per Diluted Share (Non-GAAP)** <sup>(b) (c)</sup> | $6.90 | $6.15 | 12 | $18.78 | $17.86 | 5 |
| After-tax adjustments: <sup>(d)</sup> |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government's COVID-19 vaccine distribution program | (0.25) | (0.26) | (4) | (0.66) | (0.82) | (20) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;U.S. government's kitting, storage, and distribution of ancillary supplies program and COVID-19 tests | (0.38) | (0.57) | (33) | (0.96) | (1.36) | (29) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net losses (gains) associated with McKesson Ventures' equity investments <sup>(11)</sup> |  |  |  | 0.13 | (0.49) | 127 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination of Tax Receivable Agreement with Change Healthcare <sup>(12)</sup> | (0.65) |  |  | (0.65) |  |  |
| **Adjusted Earnings per Diluted Share Excluding Certain Items (Non-GAAP)** <sup>(b)</sup> | $5.62 | $5.32 | 6% | $16.64 | $15.19 | 10% |
| Diluted weighted-average common shares outstanding | 141.0 | 153.5 | (8)% | 143.7 | 155.8 | (8)% |

---

(a)Certain computations may reflect rounding adjustments.

(b)We calculate loss per diluted common share from continuing operations attributable to McKesson Corporation (GAAP) for the three months ended December 31, 2021 using a weighted average of 151.6 million common shares, which excludes dilutive securities from the denominator due to their antidilutive effect when calculating a net loss per diluted share. We calculate adjusted earnings per diluted share (Non-GAAP) for the three months ended December 31, 2021 on a fully diluted basis, using a weighted average of 153.5 million common shares.

(c)Adjusted earnings per diluted share on an FX-adjusted basis for the three and nine months ended December 31, 2022 was $6.97 and $18.98, respectively, which excludes the foreign currency exchange effect of $0.07 and $0.20, respectively.

(d)After-tax adjustments include the following tax impacts per diluted share:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• U.S. government's COVID-19 vaccine distribution program includes income tax expense of $0.09 per diluted share for each of the three months ended December 31, 2022 and 2021, and $0.23 and $0.29 per diluted share for the nine months ended December 31, 2022 and 2021, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• U.S. government's kitting, storage, and distribution of ancillary supplies program and COVID-19 tests includes income tax expense of $0.13 and $0.20 per diluted share for the three months ended December 31, 2022 and 2021, respectively, and $0.34 and $0.48 per diluted share for the nine months ended December 31, 2022 and 2021, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net losses (gains) associated with McKesson Ventures' equity investments includes income tax benefit of $0.04 per diluted share and income tax expense of $0.17 per diluted share for the nine months ended December 31, 2022 and 2021, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Termination of Tax Receivable Agreement with Change Healthcare early termination fee includes income tax expense of $0.23 per diluted share for the three and nine months ended December 31, 2022 and 2021.

All percentage changes displayed above which are not meaningful are displayed as zero percent.

Refer to the section entitled "Financial Statement Notes" of this release.

For more information relating to the Adjusted Earnings per Diluted Share (Non-GAAP) and Adjusted Earnings per Diluted Share Excluding Certain Items (Non-GAAP) definitions, refer to the section entitled "Supplemental Non-GAAP Financial Information" of this release.

------

***<u>Schedule 2 (continued)</u>***

**McKESSON CORPORATION**

**RECONCILIATION OF GAAP OPERATING RESULTS TO ADJUSTED RESULTS (NON-GAAP)**

**(unaudited)**

**(in millions)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | | **Nine Months Ended December 31,** | **Nine Months Ended December 31,** | |
| | **2022** | **2021** |<br>**Change** | **2022** | **2021** |<br>**Change** |
| **Gross profit (GAAP)** | $3174 | $3428 | (7)% | $9292 | $9812 | (5)% |
| Pre-tax adjustments: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LIFO inventory-related adjustments | 5 | (33) | 115 | (31) | (79) | (61) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gains from antitrust legal settlements | (129) |  |  | (129) | (46) | 180 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other adjustments, net <sup>(10)</sup> |  |  |  |  | 147 | (100) |
| **Adjusted Gross Profit (Non-GAAP)** | $3050 | $3395 | (10)% | $9132 | $9834 | (7)% |
| **Total operating expenses (GAAP)** | $(1933) | $(3130) | (38)% | $(5891) | $(8407) | (30)% |
| Pre-tax adjustments: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of acquisition-related intangibles | 57 | 81 | (30) | 170 | 262 | (35) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transaction-related expenses and adjustments <sup>(1) (2) (3) (4)</sup> | (9) | 882 | (101) | (16) | 1343 | (101) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring, impairment, and related charges, net <sup>(6)</sup> | 31 | 18 | 72 | 84 | 208 | (60) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Claims and litigation charges, net <sup>(7)</sup> | (1) | 7 | (114) | (5) | 193 | (103) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other adjustments, net <sup>(10)</sup> | 20 |  |  | 26 | 9 | 189 |
| **Adjusted Operating Expenses (Non-GAAP)** | $(1835) | $(2142) | (14)% | $(5632) | $(6392) | (12)% |
| **Other income, net (GAAP)** | $276 | $20 | —% | $466 | $202 | 131% |
| Pre-tax adjustments: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of acquisition-related intangibles |  |  |  |  | 1 | (100) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transaction-related expenses and adjustments <sup>(5)</sup> |  |  |  | (142) |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other adjustments, net <sup>(8)</sup> | (98) |  |  | (97) |  |  |
| **Adjusted Other Income (Non-GAAP)** | $178 | $20 | 790% | $227 | $203 | 12% |
| **Loss on debt extinguishment (GAAP)** | $— | $— | —% | $— | $(191) | (100)% |
| Pre-tax adjustments: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other adjustments, net <sup>(9)</sup> |  |  |  |  | 191 | (100) |
| **Adjusted Loss on Debt Extinguishment (Non-GAAP)** | $— | $— | —% | $— | $— | —% |
| **Income tax expense (GAAP)** | $(329) | $(238) | 38% | $(799) | $(396) | 102% |
| Tax adjustments: |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of acquisition-related intangibles | (13) | (16) | (19) | (37) | (56) | (34) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transaction-related expenses and adjustments | (15) | 9 | (267) | 57 | (11) | 618 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LIFO inventory-related adjustments | (1) | 8 | (113) | 8 | 20 | (60) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gains from antitrust legal settlements | 34 |  |  | 34 | 12 | 183 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring, impairment, and related charges, net | (7) | (4) | 75 | (19) | (41) | (54) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Claims and litigation charges, net |  | (1) | (100) | 1 | (33) | 103 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other adjustments, net | 20 |  |  | 17 | (87) | 120 |
| **Adjusted Income Tax Expense (Non-GAAP)** | $(311) | $(242) | 29% | $(738) | $(592) | 25% |

---

All percentage changes displayed above which are not meaningful are displayed as zero percent.

Refer to the section entitled "Financial Statement Notes" of this release.

For more information relating to the Adjusted Gross Profit (Non-GAAP), Adjusted Operating Expenses (Non-GAAP), Adjusted Other Income (Non-GAAP), Adjusted Loss on Debt Extinguishment (Non-GAAP), and Adjusted Income Tax Expense (Non-GAAP) definitions, refer to the section entitled "Supplemental Non-GAAP Financial Information" of this release.

------

***<u>Schedule 3</u>***

**McKESSON CORPORATION**

**RECONCILIATION OF GAAP SEGMENT OPERATING RESULTS TO ADJUSTED RESULTS (NON-GAAP)**

**(unaudited)**

**(in millions)**

---

| | | | | | | | | | | | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | | | | | | | | | | | | |
| | **2022** | **2022** | **2022** | **2022** | **2022** | **2022** | **2021** | **2021** | **2021** | **2021** | **2021** | **2021** | **As reported** | **As reported** | **As adjusted** | **As adjusted** | **Change** | **Change** | **Change** | **Change** | **Change** | **Change** | **Change** | **Change** |
| | As reported (GAAP) | As reported (GAAP) | Adjustments | Adjustments | As adjusted (Non-GAAP) | As adjusted (Non-GAAP) | As reported (GAAP) | As reported (GAAP) | Adjustments | Adjustments | As adjusted (Non-GAAP) | As adjusted (Non-GAAP) | Foreign currency effects | FX-Adjusted (Non-GAAP) | Foreign currency effects | FX-Adjusted (Non-GAAP) | As reported (GAAP) | As reported (GAAP) | As adjusted (Non-GAAP) | As adjusted (Non-GAAP) | As reported<br>FX-Adjusted<br>(Non-GAAP) | As reported<br>FX-Adjusted<br>(Non-GAAP) | As adjusted<br>FX-Adjusted<br>(Non-GAAP) | As adjusted<br>FX-Adjusted<br>(Non-GAAP) |
| **REVENUES** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| U.S. Pharmaceutical | $| 61934 | $|  | $| 61934 | $| 55041 | $|  | $| 55041 | $— | $61934 | $— | $61934 | 13 | % | 13 | % | 13 | % | 13 | % |
| Prescription Technology Solutions | 1121 | 1121 |  |  | 1121 | 1121 | 1031 | 1031 |  |  | 1031 | 1031 |  | 1121 |  | 1121 | 9 |  | 9 |  | 9 |  | 9 |  |
| Medical-Surgical Solutions | 2986 | 2986 |  |  | 2986 | 2986 | 3082 | 3082 |  |  | 3082 | 3082 |  | 2986 |  | 2986 | (3) |  | (3) |  | (3) |  | (3) |  |
| International | 4449 | 4449 |  |  | 4449 | 4449 | 9460 | 9460 |  |  | 9460 | 9460 | 461 | 4910 | 461 | 4910 | (53) |  | (53) |  | (48) |  | (48) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenues | $| 70490 | $|  | $| 70490 | $| 68614 | $|  | $| 68614 | $461 | $70951 | $461 | $70951 | 3 | % | 3 | % | 3 | % | 3 | % |
| **OPERATING PROFIT (LOSS)** <sup>(6)</sup>  | **OPERATING PROFIT (LOSS)** <sup>(6)</sup>  | **OPERATING PROFIT (LOSS)** <sup>(6)</sup>  | **OPERATING PROFIT (LOSS)** <sup>(6)</sup>  | **OPERATING PROFIT (LOSS)** <sup>(6)</sup>  | **OPERATING PROFIT (LOSS)** <sup>(6)</sup>  | **OPERATING PROFIT (LOSS)** <sup>(6)</sup>  | **OPERATING PROFIT (LOSS)** <sup>(6)</sup>  | **OPERATING PROFIT (LOSS)** <sup>(6)</sup>  | **OPERATING PROFIT (LOSS)** <sup>(6)</sup>  | **OPERATING PROFIT (LOSS)** <sup>(6)</sup>  | **OPERATING PROFIT (LOSS)** <sup>(6)</sup>  | **OPERATING PROFIT (LOSS)** <sup>(6)</sup>  |  |  |  |  |  |  |  |  |  |  |  |  |
| U.S. Pharmaceutical | $| 850 | $| (72) | $| 778 | $| 744 | $| (9) | $| 735 | $— | $850 | $— | $778 | 14 | % | 6 | % | 14 | % | 6 | % |
| Prescription Technology Solutions | 136 | 136 | 19 | 19 | 155 | 155 | 129 | 129 | 16 | 16 | 145 | 145 |  | 136 |  | 155 | 5 |  | 7 |  | 5 |  | 7 |  |
| Medical-Surgical Solutions | 328 | 328 | 8 | 8 | 336 | 336 | 308 | 308 | 22 | 22 | 330 | 330 |  | 328 |  | 336 | 6 |  | 2 |  | 6 |  | 2 |  |
| International <sup>(1) (2) (3)</sup> | 136 | 136 | 7 | 7 | 143 | 143 | (668) | (668) | 890 | 890 | 222 | 222 | 12 | 148 | 15 | 158 | 120 |  | (36) |  | 122 |  | (29) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subtotal | 1450 | 1450 | (38) | (38) | 1412 | 1412 | 513 | 513 | 919 | 919 | 1432 | 1432 | 12 | 1462 | 15 | 1427 | 183 |  | (1) |  | 185 |  |  |  |
| Corporate expenses, net <sup>(1) (2) (3) (8)</sup> | 67 | 67 | (86) | (86) | (19) | (19) | (195) | (195) | 36 | 36 | (159) | (159) |  | 67 | (1) | (20) | 134 | 134 | (88) |  | 134 | 134 | (87) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income from continuing operations before interest expense and income taxes | $| 1517 | $| (124) | $| 1393 | $| 318 | $| 955 | $| 1273 | $12 | $1529 | $14 | $1407 | 377 | % | 9 | % | 381 | % | 11 | % |
| **OPERATING PROFIT (LOSS) AS A % OF REVENUES** | **OPERATING PROFIT (LOSS) AS A % OF REVENUES** | **OPERATING PROFIT (LOSS) AS A % OF REVENUES** | **OPERATING PROFIT (LOSS) AS A % OF REVENUES** | **OPERATING PROFIT (LOSS) AS A % OF REVENUES** | **OPERATING PROFIT (LOSS) AS A % OF REVENUES** | **OPERATING PROFIT (LOSS) AS A % OF REVENUES** | **OPERATING PROFIT (LOSS) AS A % OF REVENUES** | **OPERATING PROFIT (LOSS) AS A % OF REVENUES** | **OPERATING PROFIT (LOSS) AS A % OF REVENUES** | **OPERATING PROFIT (LOSS) AS A % OF REVENUES** | **OPERATING PROFIT (LOSS) AS A % OF REVENUES** | **OPERATING PROFIT (LOSS) AS A % OF REVENUES** |  |  |  |  |  |  |  |  |  |  |  |  |
| U.S. Pharmaceutical | 1.37 | 1.37% |  |  | 1.26 | 1.26% | 1.35 | 1.35% |  |  | 1.34 | 1.34% |  | 1.37% |  | 1.26% | 2 | bp | (8) | bp | 2 | bp | (8) | bp |
| Prescription Technology Solutions | 12.13 | 12.13 |  |  | 13.83 | 13.83 | 12.51 | 12.51 |  |  | 14.06 | 14.06 |  | 12.13 |  | 13.83 | (38) |  | (23) |  | (38) |  | (23) |  |
| Medical-Surgical Solutions | 10.98 | 10.98 |  |  | 11.25 | 11.25 | 9.99 | 9.99 |  |  | 10.71 | 10.71 |  | 10.98 |  | 11.25 | 99 |  | 54 |  | 99 |  | 54 |  |
| International | 3.06 | 3.06 |  |  | 3.21 | 3.21 | (7.06) | (7.06) |  |  | 2.35 | 2.35 |  | 3.01 |  | 3.22 | 1012 |  | 86 |  | 1007 |  | 87 |  |

---

All percentage changes displayed above which are not meaningful are displayed as zero percent.

Refer to the section entitled "Financial Statement Notes" of this release.

For more information relating to the Adjusted Segment Operating Profit (Non-GAAP), Adjusted Operating Profit (Non-GAAP), Adjusted Corporate Expenses (Non-GAAP), FX-Adjusted (Non-GAAP), and Adjusted Segment Operating Profit Margin (Non-GAAP) definitions, refer to the section entitled "Supplemental Non-GAAP Financial Information" of this release.

------

***<u>Schedule 3 (continued)</u>***

**McKESSON CORPORATION**

**RECONCILIATION OF GAAP SEGMENT OPERATING RESULTS TO ADJUSTED RESULTS (NON-GAAP)**

**(unaudited)**

**(in millions)**

---

| | | | | | | | | | | | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Nine Months Ended December 31,** | **Nine Months Ended December 31,** | **Nine Months Ended December 31,** | **Nine Months Ended December 31,** | **Nine Months Ended December 31,** | **Nine Months Ended December 31,** | **Nine Months Ended December 31,** | **Nine Months Ended December 31,** | **Nine Months Ended December 31,** | **Nine Months Ended December 31,** | **Nine Months Ended December 31,** | **Nine Months Ended December 31,** | | | | | | | | | | | | |
| | **2022** | **2022** | **2022** | **2022** | **2022** | **2022** | **2021** | **2021** | **2021** | **2021** | **2021** | **2021** | **As reported** | **As reported** | **As adjusted** | **As adjusted** | **Change** | **Change** | **Change** | **Change** | **Change** | **Change** | **Change** | **Change** |
| | As reported (GAAP) | As reported (GAAP) | Adjustments | Adjustments | As adjusted (Non-GAAP) | As adjusted (Non-GAAP) | As reported (GAAP) | As reported (GAAP) | Adjustments | Adjustments | As adjusted (Non-GAAP) | As adjusted (Non-GAAP) | Foreign currency effects | FX-Adjusted (Non-GAAP) | Foreign currency effects | FX-Adjusted (Non-GAAP) | As reported (GAAP) | As reported (GAAP) | As adjusted (Non-GAAP) | As adjusted (Non-GAAP) | As reported<br>FX-Adjusted<br>(Non-GAAP) | As reported<br>FX-Adjusted<br>(Non-GAAP) | As adjusted<br>FX-Adjusted<br>(Non-GAAP) | As adjusted<br>FX-Adjusted<br>(Non-GAAP) |
| **REVENUES** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| U.S. Pharmaceutical | $| 178940 | $|  | $| 178940 | $| 158471 | $|  | $| 158471 | $— | $178940 | $— | $178940 | 13 | % | 13 | % | 13 | % | 13 | % |
| Prescription Technology Solutions | 3205 | 3205 |  |  | 3205 | 3205 | 2844 | 2844 |  |  | 2844 | 2844 |  | 3205 |  | 3205 | 13 |  | 13 |  | 13 |  | 13 |  |
| Medical-Surgical Solutions | 8421 | 8421 |  |  | 8421 | 8421 | 8734 | 8734 |  |  | 8734 | 8734 |  | 8421 |  | 8421 | (4) |  | (4) |  | (4) |  | (4) |  |
| International | 17235 | 17235 |  |  | 17235 | 17235 | 27815 | 27815 |  |  | 27815 | 27815 | 1668 | 18903 | 1668 | 18903 | (38) |  | (38) |  | (32) |  | (32) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenues | $| 207801 | $|  | $| 207801 | $| 197864 | $|  | $| 197864 | $1668 | $209469 | $1668 | $209469 | 5 | % | 5 | % | 6 | % | 6 | % |
| **OPERATING PROFIT (LOSS)** <sup>(6)</sup> | **OPERATING PROFIT (LOSS)** <sup>(6)</sup> | **OPERATING PROFIT (LOSS)** <sup>(6)</sup> | **OPERATING PROFIT (LOSS)** <sup>(6)</sup> | **OPERATING PROFIT (LOSS)** <sup>(6)</sup> | **OPERATING PROFIT (LOSS)** <sup>(6)</sup> | **OPERATING PROFIT (LOSS)** <sup>(6)</sup> | **OPERATING PROFIT (LOSS)** <sup>(6)</sup> | **OPERATING PROFIT (LOSS)** <sup>(6)</sup> | **OPERATING PROFIT (LOSS)** <sup>(6)</sup> | **OPERATING PROFIT (LOSS)** <sup>(6)</sup> | **OPERATING PROFIT (LOSS)** <sup>(6)</sup> | **OPERATING PROFIT (LOSS)** <sup>(6)</sup> |  |  |  |  |  |  |  |  |  |  |  |  |
| U.S. Pharmaceutical <sup>(5)</sup> | $| 2442 | $| (197) | $| 2245 | $| 2186 | $| (34) | $| 2152 | $— | $2442 | $— | $2245 | 12 | % | 4 | % | 12 | % | 4 | % |
| Prescription Technology Solutions | 400 | 400 | 61 | 61 | 461 | 461 | 361 | 361 | 67 | 67 | 428 | 428 |  | 400 |  | 461 | 11 |  | 8 |  | 11 |  | 8 |  |
| Medical-Surgical Solutions <sup>(10)</sup> | 883 | 883 | 28 | 28 | 911 | 911 | 679 | 679 | 227 | 227 | 906 | 906 |  | 883 |  | 911 | 30 |  | 1 |  | 30 |  | 1 |  |
| International <sup>(1) (2) (3) (4)</sup> | 93 | 93 | 325 | 325 | 418 | 418 | (761) | (761) | 1316 | 1316 | 555 | 555 | 31 | 124 | 43 | 461 | 112 |  | (25) |  | 116 |  | (17) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subtotal | 3818 | 3818 | 217 | 217 | 4035 | 4035 | 2465 | 2465 | 1576 | 1576 | 4041 | 4041 | 31 | 3849 | 43 | 4078 | 55 |  |  |  | 56 |  | 1 |  |
| Corporate expenses, net <sup>(1) (2) (3) (7) (8)</sup> | 49 | 49 | (357) | (357) | (308) | (308) | (858) | (858) | 462 | 462 | (396) | (396) | (3) | 46 | (3) | (311) | 106 |  | (22) |  | 105 |  | (21) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income from continuing operations before interest expense and income taxes | $| 3867 | $| (140) | $| 3727 | $| 1607 | $| 2038 | $| 3645 | $28 | $3895 | $40 | $3767 | 141 | % | 2 | % | 142 | % | 3 | % |
| **OPERATING PROFIT (LOSS) AS A % OF REVENUES** | **OPERATING PROFIT (LOSS) AS A % OF REVENUES** | **OPERATING PROFIT (LOSS) AS A % OF REVENUES** | **OPERATING PROFIT (LOSS) AS A % OF REVENUES** | **OPERATING PROFIT (LOSS) AS A % OF REVENUES** | **OPERATING PROFIT (LOSS) AS A % OF REVENUES** | **OPERATING PROFIT (LOSS) AS A % OF REVENUES** | **OPERATING PROFIT (LOSS) AS A % OF REVENUES** | **OPERATING PROFIT (LOSS) AS A % OF REVENUES** | **OPERATING PROFIT (LOSS) AS A % OF REVENUES** | **OPERATING PROFIT (LOSS) AS A % OF REVENUES** | **OPERATING PROFIT (LOSS) AS A % OF REVENUES** | **OPERATING PROFIT (LOSS) AS A % OF REVENUES** |  |  |  |  |  |  |  |  |  |  |  |  |
| U.S. Pharmaceutical | 1.36 | 1.36% |  |  | 1.25 | 1.25% | 1.38 | 1.38% |  |  | 1.36 | 1.36% |  | 1.36% |  | 1.25% | (2) | bp | (11) | bp | (2) | bp | (11) | bp |
| Prescription Technology Solutions | 12.48 | 12.48 |  |  | 14.38 | 14.38 | 12.69 | 12.69 |  |  | 15.05 | 15.05 |  | 12.48 |  | 14.38 | (21) |  | (67) |  | (21) |  | (67) |  |
| Medical-Surgical Solutions | 10.49 | 10.49 |  |  | 10.82 | 10.82 | 7.77 | 7.77 |  |  | 10.37 | 10.37 |  | 10.49 |  | 10.82 | 272 |  | 45 |  | 272 |  | 45 |  |
| International | 0.54 | 0.54 |  |  | 2.43 | 2.43 | (2.74) | (2.74) |  |  | 2.00 | 2.00 |  | 0.66 |  | 2.44 | 328 |  | 43 |  | 340 |  | 44 |  |

---

All percentage changes displayed above which are not meaningful are displayed as zero percent.

Refer to the section entitled "Financial Statement Notes" of this release.

For more information relating to the Adjusted Segment Operating Profit (Non-GAAP), Adjusted Operating Profit (Non-GAAP), Adjusted Corporate Expenses (Non-GAAP), FX-Adjusted (Non-GAAP), and Adjusted Segment Operating Profit Margin (Non-GAAP) definitions, refer to the section entitled "Supplemental Non-GAAP Financial Information" of this release.

------

***<u>Schedule 4</u>***

**McKESSON CORPORATION**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(unaudited)**

**(in millions, except per share amounts)**

---

| | | |
|:---|:---|:---|
| | **December 31, 2022** | **March 31, 2022** |
| **ASSETS** | | |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $2774 | $3532 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receivables, net | 20537 | 18583 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | 20657 | 18702 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assets held for sale | 14 | 4516 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other | 675 | 898 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 44657 | 46231 |
| Property, plant, and equipment, net | 2140 | 2092 |
| Operating lease right-of-use assets | 1653 | 1548 |
| Goodwill | 9934 | 9451 |
| Intangible assets, net | 2273 | 2059 |
| Other non-current assets | 2033 | 1917 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $62690 | $63298 |
| **LIABILITIES AND DEFICIT** | **LIABILITIES AND DEFICIT** | **LIABILITIES AND DEFICIT** |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Drafts and accounts payable | $42238 | $38086 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Short-term borrowings | 617 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current portion of long-term debt | 404 | 799 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current portion of operating lease liabilities | 292 | 297 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liabilities held for sale | 2 | 4741 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other accrued liabilities | 4453 | 4543 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 48006 | 48466 |
| Long-term debt | 5452 | 5080 |
| Long-term deferred tax liabilities | 1465 | 1418 |
| Long-term operating lease liabilities | 1410 | 1366 |
| Long-term litigation liabilities | 6642 | 7220 |
| Other non-current liabilities | 1804 | 1540 |
| McKesson Corporation stockholders' deficit |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.01 par value, 800 shares authorized, 277 and 275 shares issued at December 31, 2022 and March 31, 2022, respectively | 3 | 2 |
| Additional paid-in capital | 7536 | 7275 |
| Retained earnings | 11582 | 9030 |
| Accumulated other comprehensive loss | (899) | (1534) |
| Treasury shares, at cost, 140 and 130 shares at December 31, 2022 and March 31, 2022, respectively | (20677) | (17045) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total McKesson Corporation stockholders' deficit | (2455) | (2272) |
| Noncontrolling interests | 366 | 480 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total deficit | (2089) | (1792) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and deficit | $62690 | $63298 |

---

------

***<u>Schedule 5</u>***

**McKESSON CORPORATION**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(unaudited)**

**(in millions)**

---

| | | |
|:---|:---|:---|
|  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Nine Months Ended December 31,** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Nine Months Ended December 31,** |
|  | **2022** | **2021** |
| **OPERATING ACTIVITIES** |  |  |
| Net income | $2896 | $882 |
| Adjustments to reconcile to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation | 185 | 215 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization | 262 | 383 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Long-lived asset impairment charges | 13 | 128 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred taxes | 55 | 12 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Credits associated with last-in, first-out inventory method | (31) | (79) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-cash operating lease expense | 183 | 198 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain from sales of businesses and investments | (215) | (117) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;European businesses held for sale |  | 1271 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other non-cash items | 221 | 452 |
| Changes in assets and liabilities, net of acquisitions: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receivables | (2193) | (1925) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories | (2190) | (1659) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Drafts and accounts payable | 3531 | 1612 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | (256) | (276) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Taxes | 381 | 176 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Litigation liabilities | (1021) | 146 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 13 | 128 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities | 1834 | 1547 |
| **INVESTING ACTIVITIES** |  |  |
| Payments for property, plant, and equipment | (265) | (253) |
| Capitalized software expenditures | (111) | (127) |
| Acquisitions, net of cash, cash equivalents, and restricted cash acquired | (856) | (6) |
| Proceeds from sales of businesses and investments, net | 1074 | 197 |
| Other | (140) | (83) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (298) | (272) |
| **FINANCING ACTIVITIES** |  |  |
| Proceeds from short-term borrowings | 1100 | 3642 |
| Repayments of short-term borrowings | (483) | (3270) |
| Proceeds from issuances of long-term debt | 499 | 498 |
| Repayments of long-term debt | (412) | (1646) |
| Payments for debt extinguishments |  | (184) |
| Common stock transactions: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Issuances | 143 | 174 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share repurchases | (3500) | (1986) |
| Dividends paid | (216) | (206) |
| Exercise of put right by noncontrolling shareholders of McKesson Europe AG |  | (1031) |
| Other | (309) | (323) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in financing activities | (3178) | (4332) |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 15 | 35 |
| Change in cash, cash equivalents, and restricted cash classified within Assets held for sale | 470 | (215) |
| Net decrease in cash, cash equivalents, and restricted cash | (1157) | (3237) |
| Cash, cash equivalents, and restricted cash at beginning of period | 3935 | 6396 |
| Cash, cash equivalents, and restricted cash at end of period | 2778 | 3159 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less: Restricted cash at end of period included in Prepaid expenses and other | (4) | (405) |
| Cash and cash equivalents at end of period | $2774 | $2754 |

---

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

***<u>Schedule 6</u>***

**McKESSON CORPORATION**

**RECONCILIATION OF GAAP CASH FLOW TO FREE CASH FLOW (NON-GAAP)**

**(unaudited)**

**(in millions)**

---

| | | | |
|:---|:---|:---|:---|
| | **Nine Months Ended December 31,** | **Nine Months Ended December 31,** | |
| | **2022** | **2021** |<br>**Change** |
| **GAAP CASH FLOW CATEGORIES** |  |  |  |
| Net cash provided by operating activities | $1834 | $1547 | 19% |
| Net cash used in investing activities | (298) | (272) | 10 |
| Net cash used in financing activities | (3178) | (4332) | (27) |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 15 | 35 | (57) |
| Change in cash, cash equivalents, and restricted cash classified within Assets held for sale | 470 | (215) | 319 |
| Net decrease in cash, cash equivalents, and restricted cash | $(1157) | $(3237) | (64)% |
| **FREE CASH FLOW (NON-GAAP)** |  |  |  |
| Net cash provided by operating activities | $1834 | $1547 | 19% |
| Payments for property, plant, and equipment | (265) | (253) | 5 |
| Capitalized software expenditures | (111) | (127) | (13) |
| Free Cash Flow (Non-GAAP) | $1458 | $1167 | 25% |

---

All percentage changes displayed above which are not meaningful are displayed as zero percent.

For more information relating to the Free Cash Flow (Non-GAAP) definition, refer to the section entitled "Supplemental Non-GAAP Financial Information" of this release.

------

1 of 2

**McKESSON CORPORATION**

**FINANCIAL STATEMENT NOTES**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Transaction-related expenses and adjustments for the three and nine months ended December 31, 2022 includes pre-tax net gains of $31 million ($36 million after-tax) and $66 million ($35 million after-tax), respectively, to remeasure assets and liabilities held for sale to fair value less costs to sell related to an agreement to sell certain of our European businesses to the PHOENIX Group. Pre-tax gains for the three and nine months ended December 31, 2022 of $34 million ($39 million after-tax) and $306 million ($275 million after-tax), respectively, are included within Corporate expenses, net, and charges (pre-tax and after-tax) of $3 million and $240 million, respectively, are included within International. These gains and charges are primarily to remeasure assets and liabilities held for sale to fair value less costs to sell, including the effect of accumulated other comprehensive income balances associated with the disposal group, and are included under "total operating expenses" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Transaction-related expenses and adjustments for the three and nine months ended December 31, 2021 includes pre-tax charges of $26 million ($31 million after-tax) and $517 million ($503 million after-tax), respectively, to remeasure assets and liabilities held for sale to fair value less costs to sell related to the sale of certain of our European businesses to the PHOENIX Group and to impair certain internal-use software that would not be utilized in the future. Pre-tax gains of $32 million ($27 million after-tax) and pre-tax charges of $117 million ($107 million after-tax) for the three and nine months ended December 31, 2021, respectively, primarily related to the effect of accumulated other comprehensive income balances associated with the disposal group, are included within Corporate expenses, net. Charges of $58 million (pre-tax and after-tax) and pre-tax charges of $400 million ($396 million after-tax) for the three and nine months ended December 31, 2021, respectively, primarily to remeasure assets and liabilities held for sale to fair value less costs to sell, to impair certain internal-use software that will not be utilized in the future, and the effect of accumulated other comprehensive income balances associated with the disposal group, are included within International. These net charges are included under "total operating expenses" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)Transaction-related expenses and adjustments for the three and nine months ended December 31, 2021 includes pre-tax charges of $823 million ($829 million after-tax) to remeasure assets and liabilities held for sale to fair value less costs to sell related to the sale of our retail and distribution businesses in the United Kingdom to AURELIUS, primarily within International. These charges are included under "total operating expenses" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)Transaction-related expenses and adjustments for the nine months ended December 31, 2021 includes a gain of $59 million (pre-tax and after-tax) related to the sale of our Canadian health benefit claims management and plan administrative services business within International. This gain is included under "total operating expenses" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)Transaction-related expenses and adjustments for the nine months ended December 31, 2022 includes a pre-tax gain of $142 million ($105 million after-tax) related to the exit of an investment in equity securities within U.S. Pharmaceutical. This gain is included under "other income, net" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)Restructuring, impairment, and related charges, net for the three and nine months ended December 31, 2022 includes pre-tax charges of $31 million ($24 million after-tax) and $84 million ($65 million after-tax), respectively, primarily within International and Corporate expenses, net. The three and nine months ended December 31, 2021 includes pre-tax charges of $18 million ($14 million after-tax) and $208 million ($167 million after-tax), respectively, primarily within Corporate expenses, net as well as impairment of certain long-lived assets within International. These charges are included under "total operating expenses" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.

------

2 of 2

**FINANCIAL STATEMENT NOTES (continued)**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7)Claims and litigation charges, net for the nine months ended December 31, 2021 includes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• pre-tax charges of $112 million ($93 million after-tax) related to our estimated liability for opioid-related claims of governmental entities, including Native American tribes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a pre-tax charge of $27 million ($22 million after-tax) related to an agreement to settle opioid-related claims with the State of New York and its participating subdivisions, including Nassau and Suffolk Counties; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a pre-tax charge of $47 million ($39 million after-tax) related to our estimated liability for a comprehensive proposed agreement to settle opioid-related claims of participating states, their political subdivisions, and other governmental entities.

These charges are included within Corporate expenses, net and under "total operating expenses" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(8)Other adjustments, net for the three and nine months ended December 31, 2022 includes a pre-tax gain of $97 million ($72 million after-tax) within Corporate expenses, net from termination of fixed interest rate swaps accounted for as cash flow hedges. Management believes that this gain is not part of normal business operations and is therefore excluded from our determination of adjusted results. This gain is included under "other income, net" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(9)Other adjustments, net for the nine months ended December 31, 2021 includes a pre-tax loss of $191 million ($141 million after-tax) on debt extinguishment within Corporate expenses, net related to our July 2021 tender offer to redeem a portion of our then-existing debt. This charge is included under "loss on debt extinguishment" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(10)Other adjustments, net for the nine months ended December 31, 2021 includes pre-tax charges of $155 million ($118 million after-tax) related to inventory write downs on certain excess personal protective equipment within Medical-Surgical Solutions. These charges were driven by the intent of management to not sell this excess inventory which required inventory write downs to zero net realizable value, and instead direct it to charitable organizations or otherwise dispose. A portion of this inventory was committed for donation to charitable organizations during our first quarter of fiscal 2022, which was delivered during fiscal 2022. Due to the nature of this inventory which was no longer intended for sale in a quantitatively significant amount, management believes this charge is not part of normal business operations and is therefore excluded from our determination of adjusted results. A pre-tax charge of $147 million ($112 million after-tax) is included under "gross profit" primarily related to the excess inventory, which we no longer planned to sell, and a pre-tax charge of $8 million ($6 million after-tax) is included under "total operating expenses" related to the completed donation in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(11)Net losses (gains) associated with McKesson Ventures' equity investments for the nine months ended December 31, 2022 and 2021 included pre-tax net losses of $24 million ($18 million after-tax) and pre-tax net gains of $104 million ($77 million after-tax), respectively, within Corporate expenses, net. These amounts were recorded in "Other income, net" in the Condensed Consolidated Statements of Operations (GAAP) provided in Schedule 1 of the accompanying financial statement tables.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(12)Termination of Tax Receivable Agreement ("TRA") with Change Healthcare for the three and nine months ended December 31, 2022 consists of a pre-tax gain of $126 million ($93 million after-tax) within Corporate expenses, net, related to a cash payment received as a result of an exercise of the option by Change Healthcare Inc. ("Change") pursuant to the TRA for early termination of the agreement. We entered into this agreement as part of the formation of a joint venture with Change, from which McKesson has since exited. This amount was recorded in "Other income, net" in the Condensed Consolidated Statements of Operations (GAAP) provided in Schedule 1 of the accompanying financial statement tables.

------

1 of 3

**McKESSON CORPORATION**

**SUPPLEMENTAL NON-GAAP FINANCIAL INFORMATION**

In an effort to provide investors with additional information regarding the Company's financial results as determined by generally accepted accounting principles ("GAAP"), McKesson Corporation (the "Company" or "we") also presents the following Non-GAAP measures in this press release.

**• Adjusted Gross Profit (Non-GAAP):** We define Adjusted Gross Profit as GAAP gross profit, excluding transaction-related expenses and adjustments, last-in, first-out ("LIFO") inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, and other adjustments.

**• Adjusted Operating Expenses (Non-GAAP):** We define Adjusted Operating Expenses as GAAP total operating expenses, excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, restructuring, impairment, and related charges, claims and litigation charges, and other adjustments.

**• Adjusted Other Income (Non-GAAP):** We define Adjusted Other Income as GAAP other income (expense), net, excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, and other adjustments.

**• Adjusted Loss on Debt Extinguishment (Non-GAAP):** We define Adjusted Loss on Debt Extinguishment as GAAP loss on debt extinguishment, excluding other adjustments.

**• Adjusted Income Tax Expense (Non-GAAP):** We define Adjusted Income Tax Expense as GAAP income tax benefit (expense), excluding the income tax effects of amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, claims and litigation charges, and other adjustments. Income tax effects are calculated in accordance with Accounting Standards Codification ("ASC") 740, "Income Taxes," which is the same accounting principle used by the Company when presenting its GAAP financial results.

**• Adjusted Earnings (Non-GAAP):** We define Adjusted Earnings as GAAP income (loss) from continuing operations attributable to McKesson, excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, claims and litigation charges, other adjustments as well as the related income tax effects for each of these items, as applicable.

**• Adjusted Earnings per Diluted Share (Non-GAAP):** We define Adjusted Earnings per Diluted Share as GAAP earnings (loss) per diluted common share from continuing operations attributable to McKesson, excluding per share impacts of amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, claims and litigation charges, other adjustments as well as the related income tax effects for each of these items, as applicable, divided by diluted weighted-average shares outstanding.

**• Adjusted Earnings per Diluted Share Excluding Certain Items (Non-GAAP):** We define Adjusted Earnings per Diluted Share Excluding Certain Items as Adjusted Earnings (Non-GAAP), excluding the impacts of the U.S. government's COVID-19 vaccine distribution program, the U.S. government's kitting, storage, and distribution of ancillary supplies for COVID-19 vaccines program, sales of COVID-19 tests, net gains and losses associated with McKesson Ventures' equity investments, and the gain recognized related to termination of the TRA with Change, as well as the related income tax effects for each of these items, as applicable, divided by diluted weighted-average shares outstanding.

The following provides further details regarding certain adjustments made to our Adjusted Earnings per Diluted Share (Non-GAAP) financial results to arrive at our Adjusted Earnings per Diluted Share Excluding Certain Items (Non-GAAP) as defined above:

<u>U.S. government's COVID-19 vaccine distribution program</u> - The Company distributes certain COVID-19 vaccines in support of the U.S. government through a contract with the Centers for Disease Control and Prevention. The results of operations related to this vaccine distribution program are reflected in the U.S. Pharmaceutical segment.

------

2 of 3

**SUPPLEMENTAL NON-GAAP FINANCIAL INFORMATION (continued)**

<u>U.S. government's kitting, storage, and distribution of ancillary supplies program and COVID-19 tests</u> - The Company operates under a contract to manage the assembly, storage, and distribution of ancillary supply kits for COVID-19 vaccines as directed by the Department of Health and Human Services. Sales of COVID-19 tests are also included in the Company's results of operations. These items are reflected in the Medical-Surgical Solutions segment.

**• Adjusted Segment Operating Profit (Non-GAAP) and Adjusted Segment Operating Profit Margin (Non-GAAP):** We define Adjusted Segment Operating Profit as GAAP segment operating profit (loss), excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, and other adjustments. We define Adjusted Segment Operating Profit Margin as Adjusted Segment Operating Profit (Non-GAAP) divided by GAAP segment revenues.

**• Adjusted Corporate Expenses (Non-GAAP):** We define Adjusted Corporate Expenses as GAAP corporate expenses, net, excluding transaction-related expenses and adjustments, restructuring, impairment, and related charges, claims and litigation charges, and other adjustments.

**• Adjusted Operating Profit (Non-GAAP):** We define Adjusted Operating Profit as GAAP income (loss) from continuing operations before interest expense and income taxes, excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, claims and litigation charges, and other adjustments.

The following provides further details regarding the adjustments made to our GAAP financial results to arrive at our Non-GAAP measures as defined above:

<u>Amortization of acquisition-related intangibles</u> - Amortization expenses of intangible assets directly related to business combinations and the formation of joint ventures.

<u>Transaction-related expenses and adjustments</u> - Transaction, integration, and other expenses that are directly related to business combinations, the formation of joint ventures, divestitures, and other transaction-related costs including initial public offering costs. Examples include transaction closing costs, professional service fees, legal fees, severance charges, retention payments and employee relocation expenses, facility or other exit-related expenses, certain fair value adjustments including deferred revenues, contingent consideration and inventory, recoveries of acquisition-related expenses or post-closing expenses, bridge loan fees and gains or losses on business combinations, and divestitures of businesses that do not qualify as discontinued operations.

<u>LIFO inventory-related adjustments</u> - LIFO inventory-related non-cash expense or credit adjustments.

<u>Gains from antitrust legal settlements</u> - Net cash proceeds representing the Company's share of antitrust lawsuit settlements.

<u>Restructuring, impairment, and related charges</u> - Restructuring charges that are incurred for programs in which we change our operations, the scope of a business undertaken by our business units, or the manner in which that business is conducted as well as long-lived asset impairments. Such charges may include employee severance, retention bonuses, facility closure or consolidation costs, lease or contract termination costs, asset impairments, accelerated depreciation and amortization, and other related expenses. The restructuring programs may be implemented due to the sale or discontinuation of a product line, reorganization or management structure changes, headcount rationalization, realignment of operations or products, integration of acquired businesses, and/or company-wide cost saving initiatives. The amount and/or frequency of these restructuring charges are not part of our underlying business, which include normal levels of reinvestment in the business. Any credit adjustments due to subsequent changes in estimates are also excluded from adjusted results.

<u>Claims and litigation charges</u> - Adjustments to certain of the Company's reserves, including those related to estimated probable settlements for its controlled substance monitoring and reporting, and opioid-related claims, as well as any applicable income items or credit adjustments due to subsequent changes in estimates. This does not include our legal fees to defend claims, which are expensed as incurred. This also may include charges or credits for general non-operational claims not directly related to our ongoing business.

------

3 of 3

**SUPPLEMENTAL NON-GAAP FINANCIAL INFORMATION (continued)**

<u>Other adjustments</u> - The Company evaluates the nature and significance of transactions qualitatively and quantitatively on an individual basis and may include them in the determination of our adjusted results from time to time. While not all-inclusive, other adjustments may include: other asset impairments; gains or losses from debt extinguishment; and other similar substantive and/or infrequent items as deemed appropriate.

The Company evaluates the aforementioned Non-GAAP measures on a periodic basis and updates the definitions from time to time. The evaluation considers both the quantitative and qualitative aspects of the Company's presentation of Non-GAAP adjusted results. A reconciliation of McKesson's GAAP financial results to Non-GAAP financial results is provided in Schedules 2 and 3 of the financial statement tables included with this release.

**• FX-Adjusted (Non-GAAP):** McKesson also presents its GAAP financial results and adjusted results (Non-GAAP) on an FX-Adjusted basis. To present our financial results on an FX-Adjusted basis, we convert current year period results of our operations in foreign countries, which are recorded in local currencies, into U.S. dollars by applying the average foreign currency exchange rates of the comparable prior year period. To present Adjusted Earnings per Diluted Share on an FX-Adjusted basis, we estimate the impact of foreign currency rate fluctuations on the Company's noncontrolling interests and adjusted income tax expense, which may vary from quarter to quarter. The supplemental FX-Adjusted information of the Company's GAAP financial results and adjusted results (Non-GAAP) is provided in Schedule 3 of the financial statement tables included with this release.

**• Free Cash Flow (Non-GAAP):** We define free cash flow as net cash provided by (used in) operating activities less payments for property, plant and equipment and capitalized software expenditures, as disclosed in our condensed consolidated statements of cash flows. A reconciliation of McKesson's GAAP financial results to Free Cash Flow (Non-GAAP) is provided in Schedule 6 of the financial statement tables included with this release.

The Company believes the presentation of Non-GAAP measures provides useful supplemental information to investors with regard to its operating performance, as well as assists with the comparison of its past financial performance to the Company's future financial results. Moreover, the Company believes that the presentation of Non-GAAP measures assists investors' ability to compare its financial results to those of other companies in the same industry. However, the Company's Non-GAAP measures used in the press tables may be defined and calculated differently by other companies in the same industry.

The Company internally uses both GAAP and Non-GAAP financial measures in connection with its own financial planning and reporting processes. Management utilizes Non-GAAP financial measures when allocating resources, deploying capital, as well as assessing business performance, and determining employee incentive compensation. The Company conducts its businesses internationally in local currencies, including Euro, Canadian dollars, and British pound sterling. As a result, the comparability of our results reported in U.S. dollars can be affected by changes in foreign currency exchange rates. We present FX-Adjusted information to provide a framework for assessing how our business performed excluding the estimated effect of foreign currency exchange rate fluctuations. We believe free cash flow is important to management and useful to investors as a supplemental measure as it indicates the cash flow available for working capital needs, re-investment opportunities, strategic acquisitions, dividend payments, or other strategic uses of cash. Nonetheless, Non-GAAP adjusted results and related Non-GAAP measures disclosed by the Company should not be considered a substitute for, nor superior to, financial results and measures as determined or calculated in accordance with GAAP.

<br>